ACM
AERI

Atika Capital Management’s Aerie Pharmaceuticals AERI Stock Holding History

Atika Capital Management’s Portfolio AERI Stock Details AERI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-80,000
Closed -$5.4M – 105
2018
Q2 		$5.4M Buy
+80,000
New +$4.48M 1.04% 36

Other funds holding AERI

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $33.3B AUM 44.76% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
LCS
Levin Capital Strategies New York $1.49B AUM 30.44% 1-Year Est. Return

Atika Capital Management's AERI Position: Q3 2021 in Review

Atika Capital Management sold out of Aerie Pharmaceuticals (AERI) in Q3 2021, closing a stake of 395,500 shares — an estimated $6.33M sold.

Atika Capital Management first reported a position in AERI in Q3 2016 and held it in 9 quarters. The position peaked at $8.58M in Q1 2021. 137 funds tracked by Wall St. Rank hold AERI as of Q3 2021.

  • Atika Capital Management reported no remaining Aerie Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Atika Capital Management sold 395,500 Aerie Pharmaceuticals shares in Q3 2021, an estimated $6.33M.
  • Atika Capital Management first reported a position in Aerie Pharmaceuticals in Q3 2016 and held it in 9 quarters.
  • Atika Capital Management's Aerie Pharmaceuticals position peaked at $8.58M in Q1 2021.
  • 137 funds tracked by Wall St. Rank held Aerie Pharmaceuticals as of Q3 2021.

Based on Atika Capital Management's 13F filing for Q3 2021, filed 12 Nov 2021.